A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Subjects With Major Depressive Disorder
Status:
Terminated
Trial end date:
2020-01-06
Target enrollment:
Participant gender:
Summary
This is a study with an open-label (OL) phase followed by a randomized, double-blind (DB),
placebo-controlled phase to assess efficacy and safety of SAGE-217 on relapse prevention in
adults with major depressive disorder.